Not Signed In -
Zang Fu theory |
|
|
Clinical Trial: Pharmacogenomics Blood Sampling Protocol For Irinotecan/Fluorouracil/Leucovorin(CPT-11/FU/LV).
This study is no longer recruiting patients.
|
Purpose
This protocol describes procedures for the collection of blood samples for the intent of determining genetic contribution to the safety and efficacy of CPT/FU/LV.
| Condition | Intervention | Phase |
|---|---|---|
| Colorectal Neoplasms | Procedure: Blood draw | Phase IV |
MedlinePlus related topics: Colorectal Cancer
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Further Study Details:
Primary Outcomes: Correlation of genotype with safety and efficacy measures.
Expected Total Enrollment: 137
Expected Total Enrollment: 137
Study start: April 2003
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Participation in studies employing treatment with irinotecan and a signed informed consent.
Exclusion Criteria:
- None.
Location Information
Study chairs or principal investigators
Pfizer Call Center, Study Director, Pfizer
More Information
Study ID Numbers: CPTAIV-0020-366
Last Updated: August 30, 2005
Record first received: August 29, 2005
ClinicalTrials.gov Identifier: NCT00140036
Health Authority: United States: Institutional Review Board
ClinicalTrials.gov processed this record on 2005-09-13
Last Updated: August 30, 2005
Record first received: August 29, 2005
ClinicalTrials.gov Identifier: NCT00140036
Health Authority: United States: Institutional Review Board
ClinicalTrials.gov processed this record on 2005-09-13
email this page
print this page
bookmark this page
feedback on this page
